CP 003

Drug Profile

CP 003

Alternative Names: CP003

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Caelus Health
  • Developer Caelus Health; Johnson & Johnson Innovation
  • Class Antihyperglycaemics; Diabetes mellitus vaccines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 05 Jan 2017 Caelus Health enters into a collaboration with Johnson & Johnson Innovation for the development of CP-003
  • 05 Jan 2017 Preclinical trials in Type-2 diabetes mellitus (Prevention) in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top